Regeneron Pharmaceuticals, Inc.
ANTI-IL36R ANTIBODIES

Last updated:

Abstract:

The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human Interleukin-36 receptor (IL36R). Methods for treating or preventing diseases mediated by IL36R (e.g., skin or colon inflammatory conditions such as palmo-plantar pustular psoriasis, palmoplantar pustulosis, generalized pustular psoriasis, ulcerative colitis or IBD) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.

Status:
Application
Type:

Utility

Filling date:

1 Feb 2022

Issue date:

26 May 2022